Skip to content
Investing

Viking Therapeutics Investor Profile: VK2735, Two Phase 3 Programmes and $960m of Cash

Viking Therapeutics is testing obesity drug VK2735 in Phase 3 as a weekly injection and a daily pill. It had $960m of cash at the end of September but lost $183.2m in the third quarter alone.

Line chart of Viking Therapeutics daily closing prices in the three months to 9 November 2026
Chart: BMK News, exchange data

Viking Therapeutics is a clinical-stage biotech company whose value rests on VK2735, an experimental obesity drug now in Phase 3 trials as both a weekly injection and a daily pill. It had $960m of cash and short-term investments at the end of September after a large September financing, but it has no products on sale and lost $183.2m in the third quarter alone.

What Viking does

Viking's shares trade on Nasdaq as VKTX. The company develops medicines for metabolic and endocrine diseases, and it does not yet sell anything.

Its lead drug, VK2735, acts on two gut hormone receptors, GLP-1 and GIP. Viking is testing it in two forms: an injection given once a week and a tablet taken once a day. Behind it sits VK3019, an amylin agonist, which works through another hormone pathway being explored for weight loss. The company also lists VK2809, an oral drug for metabolic and liver disease, and VK0214, for the rare disorder X-linked adrenoleukodystrophy, but it gave no update on either with its latest results.

Viking Therapeutics: share price, chart and news

The pipeline in Phase 3

ProgrammeStageSize and designTiming
VANQUISH-1 (injection, obesity)Phase 3, enrolledAbout 4,500 adults, 78 weeksCompletion expected in 2027
VANQUISH-2 (injection, obesity with type 2 diabetes)Phase 3, enrolledAbout 1,000 adults, 78 weeksCompletion expected in 2027
SUNRISE-1 and SUNRISE-2 (pill)Phase 3, started October 2026560 adults each, 68 weeksNot yet given
Maintenance study, Part 2StartedAbout 195 adultsResults expected in 2027
VK3019Phase 1Single ascending dose studyCompletion expected later in Q4 2026

The VANQUISH trials test weekly doses of 7.5 mg, 12.5 mg and 17.5 mg against placebo, with percentage change in body weight as the main goal. Viking says it enrolled about 4,500 patients in VANQUISH-1 within about five months. Extension studies of up to 52 more weeks are due to begin in the first quarter of 2027, and the VANQUISH-1 extension will include every-other-week and monthly dosing. Results from the extensions are expected in 2028.

The SUNRISE trials test daily pills of 27.5 mg, 35 mg and 55 mg. In an earlier Phase 2 study, the pill produced weight loss of up to 12.2% after 13 weeks, and up to 80% of treated people lost at least 10% of their weight, against 5% on placebo. VANQUISH-2, for people who also have type 2 diabetes, took about nine months to enrol.

In September, Part 1 of the maintenance study showed that people who switched from weekly injections to every-other-week doses kept 83% to 97% of their weight loss over 12 weeks, and those on monthly doses kept 82% to 90%, against 61% on placebo. The arms were small, at about 10 to 16 people each. Part 2, with about 195 adults, tests oral maintenance dosing.

The latest numbers

MeasureQ3 2026Q3 2025Nine months 2026Nine months 2025
Research and development$166.8m$90.0m$432.7m$191.5m
General and administrative$20.3m$8.6m$51.1m$37.1m
Net loss$183.2m$90.8m$469.5m$202.0m
Net loss per share$1.55$0.81$4.03$1.80

Research spending almost doubled from a year earlier as the large Phase 3 trials enrolled patients. The quarterly net loss doubled too.

Cash, shares and debt

Balance sheet, 30 September 2026

  • $960m cash, cash equivalents and short-term investments
  • 127.5m shares outstanding on 15 October
  • $258.75m of 2.00% convertible notes due 2032

Cash rose from $706m at the end of 2025 because of the September financing, which raised about $575m gross and about $550m net. Viking sold 9,035,714 shares at $35.00, with Morgan Stanley and J.P. Morgan leading the deal, and issued $258.75m of convertible notes that pay 2.00% a year and mature on 15 October 2032. The notes convert at about $50.75 a share, roughly 45% above the share sale price, so full conversion would create about 5.1m more shares.

Viking can settle conversions in cash, shares or both, and from 22 October 2029 it can redeem the notes if its shares trade above 130% of the conversion price under set conditions. The money is earmarked for VK2735, VK3019 and general research and corporate costs. The company said the money gives it the runway to run several Phase 3 trials.

The $960m is a little more than five times the third-quarter net loss, although accounting losses and cash spending are not the same. How long it lasts will depend on the cost of four Phase 3 trials, their extension studies and any preparation for a launch.

Risks and what to watch

Main risks

  • Trial risk. VK2735 has not yet reported Phase 3 results, and late-stage trials can fail or show more side effects than earlier ones.
  • Heavy losses. Viking lost $469.5m in nine months with no revenue.
  • Dilution and debt. The September share sale added about 9m shares, the notes could add about 5.1m, and further raises may be needed before any launch.
  • Competition. Obesity drugs from much larger companies are already on the market, and many rivals are developing new ones.
  • Small maintenance data. The every-other-week and monthly results come from small groups over 12 weeks.
WhenWhat
14 to 15 November 2026ObesityWeek posters on VANQUISH-2 baseline data and earlier VENTURE results
Later in Q4 2026Completion of the VK3019 single ascending dose study
Q1 2027Start of VANQUISH extension studies and a 28-day VK3019 multiple ascending dose study
2027Completion of VANQUISH-1 and VANQUISH-2, and maintenance Part 2 results
2028Results from the VANQUISH extension studies

Sources

Related stories

Business

Viking Therapeutics Raises $575m After Its Obesity Drug Holds Weight Off on Monthly Doses

Viking Therapeutics sold $316m of shares at $35 and $259m of 2% convertible notes, priced a day after data showing patients kept most of their weight loss on monthly or…

Investing

Novavax Investor Profile: Sanofi Royalties, the Matrix-M Adjuvant and $627m of Cash

Novavax now earns most of its money from partners led by Sanofi. It ended September with $627m of cash and $292.1m of long-term debt; its numbers, milestones, risks and dates to…

Investing

Kraig Biocraft Laboratories Profile: Spider Silk From Silkworms, Still Before Revenue

Kraig Biocraft Laboratories breeds silkworms that spin spider silk and farms them in Vietnam. It has begun shipping yarn but reported no revenue in the first half and carries a…

Investing

Thesis Gold & Silver: Investor Profile of the Lawyers-Ranch Gold-Silver Developer in BC

Thesis Gold & Silver is advancing the Lawyers-Ranch gold-silver project in British Columbia. Its study numbers, C$121.7m cash, share count, shareholders, risks and the dates to…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…